Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer

Journal article

Peer reviewed

B. J. Monk, T. J. Herzog, S. B. Kaye, C. N. Krasner, J. B. Vermorken, F. Muggia, E. Pujade-Lourraine, P. Zintl, T. V. Parekh and A. Poveda

Journal of clinical oncology, Vol.29(15_suppl), pp.5046-5046

05/20/2011

Abstract

Abstract only

1 Record Views

Title: Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer
Creators: B. J. Monk
T. J. Herzog
S. B. Kaye
C. N. Krasner
J. B. Vermorken
F. Muggia
E. Pujade-Lourraine
P. Zintl
T. V. Parekh
A. Poveda
Publication Details: Journal of clinical oncology, Vol.29(15_suppl), pp.5046-5046
Identifiers: 991005968791602656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article